Investing by design
Why Sanofi-Genzyme BioVentures backed immunotherapy play Immune Design
Sanofi-Genzyme BioVentures hopes last week's investment in the $32.5 million first close of immunotherapy play Immune Design Corp.'s planned $49 million series C round will advance the fund's goal of filling parent Sanofi's pipeline.
Existing investor The Column Group and new investor Topspin Partners led the round. Existing investors Alta Partners, Versant Ventures,
